Literature DB >> 10485309

Outcome predictors in pregnant opiate and polydrug users.

J E McCarthy1, C Siney, N J Shaw, S M Ruben.   

Abstract

A retrospective case note study of 93 women was performed in order to assess the effect of maternal factors on neonatal outcome in a group of women attending a specialist clinic for pregnant drug users. There were no significant differences in outcome for chaotic drug users compared with non-chaotic drug users, or for cocaine users compared with non-cocaine using drug users. Women who reduced their methadone dose during pregnancy delivered babies of significantly higher birth weight than those whose methadone dose remained the same or increased (median 3027 g, range 1780-3629 g vs 2645 g, range 580-3720 g). Women who abused benzodiazepines during pregnancy produced babies of significantly lower birth weight than those women who did not use benzodiazepines (median 2100 g, range 580-3520 g vs 2767 g, range 1530-3720 g). The results of this study give healthcare staff evidence to use in encouraging drug-using women to avoid benzodiazepines during pregnancy and to reduce their methadone dosage. The treatment received from a specialist clinic may mitigate against some of the other recognised effects of drug use during pregnancy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10485309     DOI: 10.1007/s004310051193

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  8 in total

1.  Characteristics of drug use among pregnant women in the United States: Opioid and non-opioid illegal drug use.

Authors:  Verena E Metz; Qiana L Brown; Silvia S Martins; Joseph J Palamar
Journal:  Drug Alcohol Depend       Date:  2017-12-27       Impact factor: 4.492

Review 2.  Migraine during pregnancy: options for therapy.

Authors:  Anthony W Fox; Merle L Diamond; Egilius L H Spierings
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

3.  Consumption of coffee during pregnancy: authors should adjust for history of drug abuse.

Authors:  Michael Sindos; Narendra Pisal; Stavroula Michala
Journal:  BMJ       Date:  2003-06-07

4.  Pilot trial of gabapentin for the treatment of benzodiazepine abuse or dependence in methadone maintenance patients.

Authors:  John J Mariani; Robert J Malcolm; Agnieszka K Mamczur; Jean C Choi; Ronald Brady; Edward Nunes; Frances R Levin
Journal:  Am J Drug Alcohol Abuse       Date:  2016-03-10       Impact factor: 3.829

Review 5.  Pharmacologic management of the opioid neonatal abstinence syndrome.

Authors:  Walter K Kraft; John N van den Anker
Journal:  Pediatr Clin North Am       Date:  2012-08-30       Impact factor: 3.278

6.  Jail incarceration and birth outcomes.

Authors:  Janice F Bell; Frederick J Zimmerman; Mary Lawrence Cawthon; Colleen E Huebner; Deborah H Ward; Carole A Schroeder
Journal:  J Urban Health       Date:  2004-12       Impact factor: 3.671

7.  Skin conductance in neonates suffering from abstinence syndrome and unexposed newborns.

Authors:  Nicola Elisabeth Schubach; Katrin Mehler; Bernhard Roth; Eckhard Korsch; Rainhard Laux; Dominique Singer; Axel von der Wense; András Treszl; Christoph Hünseler
Journal:  Eur J Pediatr       Date:  2016-03-30       Impact factor: 3.183

8.  Would induction of dopamine homeostasis via coupling genetic addiction risk score (GARS®) and pro-dopamine regulation benefit benzodiazepine use disorder (BUD)?

Authors:  K Blum; M Gold; E J Modestino; D Baron; B Boyett; D Siwicki; L Lott; A Podesta; A K Roy; M Hauser; B W Downs; R D Badgaiyan
Journal:  J Syst Integr Neurosci       Date:  2018-05-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.